- Annual NHI drug price revisions
- High prices for energy resources and raw materials
- Foreign exchange effects from the yen’s depreciation
- Unstable supplies of generic drugs stemming from quality issues at some companies
- Low price-book value ratio (PBR) below 1x
KYORIN Pharmaceutical Co., Ltd.
Greenhouse gas emissions & sustainability report data
In its 2023-04 to 2024-03 reporting, KYORIN Pharmaceutical Co., Ltd. disclosed greenhouse gas emissions of 25.0K tons/year (Scope 1+2). By scope: Scope 1: 12.9K tCO2e/year; Scope 2: 12.1K tCO2e/year; Scope 3: 16.8K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
25.0K tons/year (Scope 1+2)
2023-04 to 2024-03
Water Usage
219.0K m3/year
2023-04 to 2024-03
Waste
834 tons/year
2023-04 to 2024-03
Energy Use
527.8K GJ/year
2023-04 to 2024-03
📊 Emissions by Scope (2023-04 to 2024-03)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 12.9K tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 12.1K tCO2e/year |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 16.8K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023-04 to 2024-03 | 25.0K tons/year (Scope 1+2) |
| 2019-04 to 2020-03 | 27.5K tCO2e/year |
| 2016-04-01 to 2017-03-31 | 18.2K tCO2e/year |
| 2015-04-01 to 2016-03-31 | 19.8K tCO2e/year |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced CO2 emissions by 25.5% compared with the level of fiscal 2015 (Scope 1 + Scope 2)
🎯 Climate & Sustainability Targets
🔜 Short-term
- Increase ratio of new drugs to at least 50% by fiscal 2025
- Achieve operating profit before deduction of R&D expenses of at least 16% by fiscal 2025
- Reduce CO2 emissions by at least 20% compared with the level of fiscal 2015 by fiscal 2025
- Have at least 50% of eligible male employees take their childcare leave by fiscal 2025
- Have at least 10% of management positions filled by women by 2030
📅 Medium-term
- Achieve carbon neutrality by 2050, with an interim target of a 46% reduction in CO2 emissions by fiscal 2030 (from the fiscal 2015 level)
🔭 Long-term
- Carbon neutrality by 2050
🌱 ESG Focus Areas
EnvironmentalSocialGovernance